Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands		Total		Underwritten Public Offering	Warrant Redemption	Roivant Sciences Ltd. (RSL)	Series A  preferred stock	Common stock		Common stock Underwritten Public Offering	Common stock Upon Achievement of Earnout Shares Milestone	Common stock Warrant Redemption	Common stock subscribed	Additional paid-in capital		Additional paid-in capital Underwritten Public Offering	Additional paid-in capital Upon Achievement of Earnout Shares Milestone	Additional paid-in capital Warrant Redemption	Additional paid-in capital Roivant Sciences Ltd. (RSL)	Accumulated other comprehensive income (loss)		Accumulated deficit
Beginning balance (in shares) at Mar. 31, 2019	[1]							38,590,381
Beginning balance at Mar. 31, 2019	[1]	$ 7,339						$ 4					$ (3)	$ 31,830						$ 346		$ (24,838)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Capital contribution – stock-based compensation	[1]	35												35
Capital contribution – expenses allocated from Roivant Sciences Ltd.	[1]					$ 331													$ 331
Stock-based compensation	[1]	537												537
Foreign currency translation adjustments	[1]	(291)																		(291)
Net loss	[1]	(20,059)																				(20,059)
Ending balance (in shares) at Jun. 30, 2019	[1]							38,590,381
Ending balance at Jun. 30, 2019	[1]	(12,108)						$ 4					(3)	32,733						55		(44,897)
Beginning balance (in shares) at Mar. 31, 2019	[1]							38,590,381
Beginning balance at Mar. 31, 2019	[1]	7,339						$ 4					(3)	31,830						346		(24,838)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(34,541)
Ending balance (in shares) at Sep. 30, 2019								38,590,381
Ending balance at Sep. 30, 2019		(23,283)						$ 4					0	36,090						2		(59,379)
Beginning balance (in shares) at Jun. 30, 2019	[1]							38,590,381
Beginning balance at Jun. 30, 2019	[1]	(12,108)						$ 4					(3)	32,733						55		(44,897)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Settlement of common share subscription		3											3
Capital contribution – stock-based compensation		18												18
Capital contribution – expenses allocated from Roivant Sciences Ltd.						220													220
Stock-based compensation		3,119												3,119
Foreign currency translation adjustments		(53)																		(53)
Net loss		(14,482)																				(14,482)
Ending balance (in shares) at Sep. 30, 2019								38,590,381
Ending balance at Sep. 30, 2019		(23,283)						$ 4					0	36,090						2		(59,379)
Beginning balance (in shares) at Mar. 31, 2020	[1]						10,000	54,655,376
Beginning balance at Mar. 31, 2020		94,069	[1],[2]					$ 5	[1]				0	185,306	[1]					(16)	[1]	(91,226)	[1]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock (in shares)	[1]									9,613,365	10,000,000	5,719,145
Issuance of common stock	[1]			$ 130,428	$ 65,752					$ 1	$ 1	$ 1				$ 130,427	$ (1)	$ 65,751
Vesting of sponsor restricted shares (in shares)	[1]							900,000
Stock options exercised (in shares)	[1]							23,841
Stock options exercised	[1]	63												63
Capital contribution – stock-based compensation	[1]	63												63
Capital contribution – expenses allocated from Roivant Sciences Ltd.	[1]					164													164
Stock-based compensation	[1]	3,918												3,918
Foreign currency translation adjustments	[1]	26																		26
Net loss	[1]	(26,708)																				(26,708)
Ending balance (in shares) at Jun. 30, 2020	[1]						10,000	80,911,727
Ending balance at Jun. 30, 2020		267,775	[1]					$ 8	[1]				0	385,691	[1]					10	[1]	(117,934)	[1]
Beginning balance (in shares) at Mar. 31, 2020	[1]						10,000	54,655,376
Beginning balance at Mar. 31, 2020		$ 94,069	[1],[2]					$ 5	[1]				0	185,306	[1]					(16)	[1]	(91,226)	[1]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock options exercised (in shares)		42,213
Net loss		$ (47,497)
Ending balance (in shares) at Sep. 30, 2020							10,000	97,890,705
Ending balance at Sep. 30, 2020		438,406	[2]					$ 10					0	577,341						(222)		(138,723)
Beginning balance (in shares) at Jun. 30, 2020	[1]						10,000	80,911,727
Beginning balance at Jun. 30, 2020		267,775	[1]					$ 8	[1]				0	385,691	[1]					10	[1]	(117,934)	[1]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock (in shares)										6,060,606	10,000,000
Issuance of common stock				$ 188,119						$ 1	$ 1					$ 188,118	$ (1)
Vesting of sponsor restricted shares (in shares)								900,000
Stock options exercised (in shares)								18,372
Stock options exercised		119												119
Capital contribution – stock-based compensation		54												54
Capital contribution – expenses allocated from Roivant Sciences Ltd.						$ 53													$ 53
Stock-based compensation		3,307												3,307
Foreign currency translation adjustments		(232)																		(232)
Net loss		(20,789)																				(20,789)
Ending balance (in shares) at Sep. 30, 2020							10,000	97,890,705
Ending balance at Sep. 30, 2020		$ 438,406	[2]					$ 10					$ 0	$ 577,341						$ (222)		$ (138,723)

[1] Retroactively restated for reverse recapitalization as described in Note 1.

[2] Retroactively restated for the reverse recapitalization as described in Note 1.